Basel, Switzerland – Alentis Therapeutics , a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Dr. William Pao will join its Board of Directors as an independent member effective immediately.
Dr. William Pao is recognized for his ground-breaking work in translational medicine, mechanistic and clinical studies of targeted cancer therapeutics, cancer genomics and personalized medicine. As Chief Development Officer and Executive Vice President for Pfizer, he was a member of the Executive Leadership Team and led the Global Product Development organization, as well as regulatory affairs. As Head of the Roche Pharma Research & Early Development (pRED) unit, he was a member of the Enlarged Corporate Executive Committee and oversaw the discovery and early development of new molecular entities across multiple therapeutic areas. At pRED, he also served as the Global Head of the Oncology Discovery and Translational Area.
Read more in the official press release.
